All In Biotech

Drug Trial Radar · NCT00444925

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)

Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,712 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,712

Actual

Start

Apr 2007

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

Conditions

  • Overactive Bladder

Interventions

  • fesoterodine fumarateDrug

    4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks

  • placeboDrug

    once daily (OD)for 12 weeks

  • tolterodine tartrateDrug

    4 mg once daily (OD) for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).Time frame: Baseline, Week 12

Locations

178 sites in 29 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Homewood, Alabama

  • Pfizer Investigational Site

    Huntsville, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Carmichael, California

  • Pfizer Investigational Site

    Orangevale, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Waterbury, Connecticut

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Wellington, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Coeur d'Alene, Idaho

  • Pfizer Investigational Site

    Sandpoint, Idaho

  • Pfizer Investigational Site

    Aurora, Illinois

  • Pfizer Investigational Site

    West Des Moines, Iowa

  • Pfizer Investigational Site

    Newton, Kansas

  • Pfizer Investigational Site

    Shrevport, Louisiana

  • Pfizer Investigational Site

    Watertown, Massachusetts

  • Pfizer Investigational Site

    Chaska, Minnesota

  • Pfizer Investigational Site

    Lawrenceville, New Jersey

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Garden City, New York

  • Pfizer Investigational Site

    Mineola, New York

  • Pfizer Investigational Site

    Burlington, North Carolina

  • Pfizer Investigational Site

    Concord, North Carolina

  • Pfizer Investigational Site

    Huntersville, North Carolina

  • Pfizer Investigational Site

    Dayton, Ohio

  • Pfizer Investigational Site

    Allentown, Pennsylvania

  • Pfizer Investigational Site

    Allentown, Pennsylvania

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

  • Pfizer Investigational Site

    East Providence, Rhode Island

  • Pfizer Investigational Site

    Charleston, South Carolina

  • Pfizer Investigational Site

    Columbia, South Carolina

  • Pfizer Investigational Site

    Kingsport, Tennessee

  • Pfizer Investigational Site

    Milan, Tennessee

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    Provo, Utah

  • Pfizer Investigational Site

    Chesapeake, Virginia

  • Pfizer Investigational Site

    Seattle, Washington

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.